Abbott Adds To Renal Pipeline In Deal With Action Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
For a single $110 million payment, the soon-to-be-split Abbott gets global rights to AP214, a Phase IIb compound designed to prevent acute kidney damage caused by hypoxia during cardiac surgery.
You may also be interested in...
Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy
The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.
Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion
New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.
Abbott Spin-Off AbbVie To Remain Close To Its Roots
Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.